ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Aprea Therapeutics Inc

Aprea Therapeutics Inc (APRE)

4.32
-0.14
(-3.14%)
Closed June 12 4:00PM
4.32
0.00
( 0.00% )
Pre Market: 4:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.32
Bid
2.08
Ask
5.00
Volume
-
0.00 Day's Range 0.00
2.78 52 Week Range 8.8465
Market Cap
Previous Close
4.32
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
9,550
Shares Outstanding
3,736,673
Dividend Yield
-
PE Ratio
-1.13
Earnings Per Share (EPS)
-3.82
Revenue
583k
Net Profit
-14.29M

About Aprea Therapeutics Inc

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for h... Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Aprea Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker APRE. The last closing price for Aprea Therapeutics was $4.32. Over the last year, Aprea Therapeutics shares have traded in a share price range of $ 2.78 to $ 8.8465.

Aprea Therapeutics currently has 3,736,673 shares outstanding. The market capitalization of Aprea Therapeutics is $16.14 million. Aprea Therapeutics has a price to earnings ratio (PE ratio) of -1.13.

APRE Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3-6.493506493514.624.70994.2573284.47783686CS
4-1.48-25.51724137935.85.94.2591934.89036599CS
12-2.35-35.23238380816.676.84.2595505.59127234CS
260.348.542713567843.988.84653.5099226366.20785904CS
521.0632.51533742333.268.84652.78254454.78841931CS
156-98.48-95.7976653696102.81562.7860535079.6266207CS
260-304.88-98.6028460543309.21062.22.78546560118.66054085CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NCINeo Concept International Group Holdings Ltd
$ 1.025
(57.06%)
9.77M
LGVNLongeveron Inc
$ 2.37
(30.94%)
3.34M
DUOFangDD Network Group Ltd
$ 0.7663
(25.62%)
2.85M
NXUNXU Inc
$ 0.4659
(16.48%)
958.84k
MOLNMolecular Partners AG
$ 6.72
(15.86%)
204.03k
IONMAssure Holdings Corporation
$ 0.2338
(-54.42%)
679.59k
CARACara Therapeutics Inc
$ 0.5434
(-20.03%)
3k
NAVINavient Corporation
$ 11.70
(-19.14%)
1
PRFXPainReform Ltd
$ 0.6298
(-16.81%)
33.81k
PTPIPetros Pharmaceuticals Inc
$ 0.45
(-16.33%)
86.06k
NCINeo Concept International Group Holdings Ltd
$ 1.025
(57.06%)
9.77M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 8.33
(10.33%)
3.5M
LGVNLongeveron Inc
$ 2.37
(30.94%)
3.34M
DUOFangDD Network Group Ltd
$ 0.7663
(25.62%)
2.85M
TSLATesla Inc
$ 186.53
(5.21%)
1.81M

APRE Discussion

View Posts
Monksdream Monksdream 3 months ago
APRE 10Q due March 14
šŸ‘ļø0
TheFinalCD TheFinalCD 3 months ago
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers $APRE https://t.co/bcQ3BoQFYX— Health Stocks News (@health_stocks) March 11, 2024
šŸ‘ļø0
RIOgrande44 RIOgrande44 11 months ago
Thanks, do you have a link?
šŸ‘ļø0
Hercules1 Hercules1 11 months ago
Analysts giving this a price target of $20.


Yes $20.


Let that sink in.
šŸ‘ļø0
willlbone willlbone 2 years ago
Dropping like a waterfall.
šŸ‘ļø0
Nazirite Nazirite 2 years ago
APRE is climbing, it climbed today in spite of a sale off going on. Holding should increase your PPS
IMO
šŸ‘ļø0
Nazirite Nazirite 2 years ago
Price target set for $3 buy and hold rating from last week
https://www.marketbeat.com/stocks/NASDAQ/APRE/
šŸ‘ļø0
Nazirite Nazirite 2 years ago
GM APRE time to work
šŸ‘ļø0
Nazirite Nazirite 2 years ago
GM APRE time to work
šŸ‘ļø0
Nazirite Nazirite 2 years ago
High volume today 43x avg
šŸ‘ļø0
Nazirite Nazirite 2 years ago
$APRE PT $3 can we see $2.40 today / Monday?
šŸ‘ļø0
Nazirite Nazirite 2 years ago
$APRE PT $3 can we see $2.40 today / Monday?
šŸ‘ļø0
Nazirite Nazirite 2 years ago
Hot Day for $APRE
insider buying and 40x average volume today so far
šŸ‘ļø0
Nazirite Nazirite 2 years ago
Aprea Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a $3 price target
šŸ‘ļø0
subslover subslover 2 years ago
Very strong!
šŸ‘ļø0
stockforce stockforce 2 years ago
Why? Any insider good news?
šŸ‘ļø0
MonopolyTrader MonopolyTrader 2 years ago
Iā€™m joining in
šŸ‘ļø0
TheFinalCD TheFinalCD 2 years ago
coming off 53w low 1.46 just on thursday

https://ih.advfn.com/stock-market/NASDAQ/aprea-therapeutics-APRE/historical
šŸ‘ļø0
Jimmy Quick Jimmy Quick 3 years ago
$APRE 8 Catalyst on the way not including the potential buyout here. CEO Chris Schlade has sold his last 3 companies to BIG PHARMA. A lot of trials on going that have had "KNOCK YOUR SOCKS OFF RESULTS" Come see us on ST for more information and great DD.





šŸ‘ļø0
crudeoil24 crudeoil24 3 years ago
Aprea Therapeutics, Inc. (NASDAQ: APRE): Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies (Monday, Sept. 20, at 11:35-11:40 am)
šŸ‘ļø0
dinogreeves dinogreeves 3 years ago
On heavy watch for Monday.
šŸ‘ļø0
stockforce stockforce 3 years ago
If the Monday data can be very promising, this will blow up.
šŸ‘ļø0
DailyX DailyX 3 years ago
This could get some nice legs over 6+, next week could be very interesting..
šŸ‘ļø0
stockforce stockforce 3 years ago
Good luck to all! Looks very promising!
šŸ‘ļø0
NATURES WAY NATURES WAY 3 years ago
Something special going on here with the gap n trap shake and bake BS.
institutions playing big time.
šŸ‘ļø0
Jimmy Quick Jimmy Quick 3 years ago
CASH ON HAND $77 MILLION
This company is sitting on $77 million in raised capital for research and trials. As noted in previous emails they have several trials ongoing, the most recent one was a success, and more to look forward to with that one in 2nd half of 2021.
šŸ‘ļø0
Jimmy Quick Jimmy Quick 3 years ago
Overview

We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, the most commonly mutated gene in cancer. We believe that mutant p53 is an attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with mutant p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains.

Our lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. Eprenetapopt has received orphan drug, fast track and breakthrough therapy designations from the FDA for MDS, orphan drug and fast track designations from the FDA for AML and orphan drug designation from the European Commission for MDS and AML, and we believe eprenetapopt will be a first-in-class therapy if approved by applicable regulators.

We are conducting, supporting and planning multiple clinical trials of eprenetapopt and APR-548:


--- Phase 3 Frontline MDS Trial -- In June 2020, we completed full enrollment of 154 patients in a pivotal Phase 3 trial of eprenetapopt with azacitidine for frontline treatment of TP53 mutant MDS. The pivotal Phase 3 trial is supported by data from two Phase 1b/2 investigator-initiated trials, one in the U.S. and one in France, testing eprenetapopt with azacitidine as frontline treatment in TP53 mutant MDS and AML patients. The data from the U.S. and French Phase 1b/2 trials were published in The Journal of Clinical Oncology in January 2021 and February 2021, respectively. In December 2020, we announced that our pivotal Phase 3 trial failed to meet its predefined primary endpoint of complete remission (CR) rate. Analysis of the primary endpoint at this data cut demonstrated a higher CR rate (53% more patients achieving a CR) in the experimental arm receiving eprenetapopt with azacitidine versus the control arm receiving azacitidine alone but did not reach statistical significance. Based on a thorough analysis of the current Phase 3 trial data and comparisons to the U.S. and French Phase 1b/2 trials, we believe that despite similar types and frequency of adverse events observed in the Phase 3 experimental arm and the Phase 1b/2 trials, patients in the Phase 3 experimental arm experienced substantially more study treatment dose modifications compared to the experience in the U.S. and French Phase 1b/2 trials. We believe that the dose modifications of eprenetapopt and azacitidine led to undertreatment in the Phase 3 experimental arm that negatively impacted efficacy, particularly the primary endpoint of CR rate. We continue to follow patients who remain on-study and anticipate discussing with FDA the Phase 3 data and future possible regulatory pathways in the second half of 2021.


--- Phase 2 MDS/AML Post-Transplant Trial -- We have completed enrollment of 33 patients in a single-arm, open-label Phase 2 trial evaluating eprenetapopt with azacitidine as post-transplant maintenance therapy in TP53 mutant MDS and AML patients who have received an allogeneic stem cell transplant. The primary endpoint of the trial is the rate of relapse-free survival (RFS) at 12 months, with a published benchmark of ~30%. An interim analysis in April 2021 showed a 62% rate of RFS at 12 months, with a median RFS of 462 days. An interim analysis of overall survival (OS) showed a 77% OS at 1 year, with a median number of events not yet reached. We anticipate initial results from the primary endpoint of RFS at 12 months in the second quarter of 2021.


---- Phase 1/2 AML Trial -- We are currently enrolling a Phase 1/2 clinical trial evaluating the safety, tolerability, and preliminary efficacy of eprenetapopt therapy in TP53 mutant AML patients. The lead-in portion of the trial evaluated the tolerability of eprenetapopt with venetoclax, with or without azacitidine, and no dose-limiting toxicities were observed in 12 patients receiving either regimen. Based on these results, we have expanded the trial to treat 33 additional frontline TP53 mutant AML patients with the combination of eprenetapopt, venetoclax and azacitidine. In the 19 frontline AML patients who are evaluable for efficacy with the triplet regimen, we have observed a 63% CR + CRi composite response rate and a 31% CR rate. We anticipate completion of enrollment in the triplet regimen expansion cohort during the second quarter of 2021 and availability of preliminary response rate data from the cohort also in the second quarter of 2021.


--- Phase 1 NHL Trial -- We are currently enrolling a Phase 1 clinical trial in relapsed/refractory TP53 mutant chronic lymphoid leukemia (CLL) assessing eprenetapopt with venetoclax and rituximab and eprenetapopt with ibrutinib in order to further assess eprenetapopt in hematological malignancies. The first patient was enrolled in the first quarter of 2021. We are also planning to evaluate the combination of eprenetapopt with venetoclax in relapsed/refractory mantle cell lymphoma.


--- Phase 1/2 Solid Tumor Trial ā€“ We are currently enrolling a Phase 1/2 clinical trial in relapsed/refractory gastric, bladder and non-small cell lung cancers assessing eprenetapopt with anti-PD-1 therapy. The dose-escalation phase of the trial enrolled 6 patients with advanced solid tumors and no dose-limiting toxicities were observed. Based on these results, we are enrolling expansion cohorts for patients with advanced gastric, bladder and non-small cell lung cancers and have currently enrolled 15 patients across these expansion arms. A poster presentation for this trial has been accepted for presentation at the 2021 ASCO Annual Meeting (abstract TPS3161).


--- APR-548 Phase 1 Trial ā€“ Our second product candidate, APR-548, is a next generation p53 reactivator that is being developed in an oral dosage form. We have planned a Phase 1 dose-escalation clinical trial evaluating safety, tolerability, and preliminary efficacy of APR-548 with azacitidine in frontline and relapsed/refractory MDS patients. We anticipate the first patient to be enrolled in the second quarter of 2021.
šŸ‘ļø0
Jimmy Quick Jimmy Quick 3 years ago
I know this isn't a NASDAQ message board. But some would have to feel that this could produce some good returns yet in CY 2021. Article today talked about how Aprea could have significant volatility approaching, signaling that a major move could be coming one way or the other. I think we know which way it would go with the news from 6/16/21.
šŸ‘ļø0
Jimmy Quick Jimmy Quick 3 years ago
Totally agree, I have been loading up at these prices. This was a $30 stock pre-failure of the last trial back in December 20. With yesterday's news of trial success for a different disease, I think we could move back to those levels in 2nd half of 2021.
šŸ‘ļø0
Roadtojourney Roadtojourney 3 years ago
Pump and dump pos imo??
šŸ‘ļø0
NATURES WAY NATURES WAY 3 years ago
sold some APRE on the pop today.
šŸ‘ļø0
NATURES WAY NATURES WAY 3 years ago
loaded shares of apre today. Seems to be corelated with the $rut.
šŸ‘ļø0
Natureboy1 Natureboy1 3 years ago
Got my order in at $20+.
šŸ‘ļø0
lukin4winners lukin4winners 3 years ago
APRE is extemely undervalued chart shows the significant upside. With 10M float no brainer.



https://schrts.co/RWyDbWtr
šŸ‘ļø0
aristotelisonassis aristotelisonassis 3 years ago
ready to fill that huge gap.
Dont miss it ladies and gents.
Strong buy here.
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
I agree. This stock is demanding attention and it will get it. People are recognizing this as being oversold and there is a new round of stimulus checks being pumped into the economy. The wash sale rules are getting close and the institutions will have to put the money somewhere. This is a institutional play. They are heavy into this company and the cash reserves are in place. This appears to be a no brainer. I am pretty confident that we will be making a good return.
šŸ‘ļø0
toytundra toytundra 3 years ago
I'm in @ 5.69 looks good from here
šŸ‘ļø0
aristotelisonassis aristotelisonassis 3 years ago
APRE Chart and indicators looks ready for a huge upside move in the next days. Buying a starter position and watching closely.
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
Jan 28th marks the end of the waiting period for institutional wash sale. I think that $APRE is going to be reentered into many of their mutual funds. The opportunity to purchase shares at low entry is closing. I believe the momentum is growing and that there will be a significant upside swing.
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
Jan 28th marks the end of the waiting period for institutional wash sale. I think that $APRE is going to be reentered into many of their mutual funds. The opportunity to purchase shares at low entry is closing. I believe the momentum is growing and that there will be a significant upside swing.
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
Another buying opportunity has appeared. Looking forward to some positive news on these trials. The convention went well in my opinion. I was impressed by the conservation of the companies cash position. Also by placing a higher amount of people in the study may result in a better understanding of what works and doesn't.
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
Welcome! There is alot of information on the company's website. The idea of holding for a year seems really smart. Your bound to have some positive returns in such a long timeframe. They are financially sound and seem to be efficient in the daily operations and monitoring the cash burn rate. It seems like an oversold position that will spike with some positive news. There is institutional interest and positions. I am excited to see this in a years time. I feel like there will be many others to join the ride along the way. Again. Welcome, and I am looking forward to seeing more posts from you and others. Good luck to us all!
šŸ‘ļø0
Harbor6460 Harbor6460 3 years ago
Hello just found this company on another bio board VS@M. Looks like a lot to offer over the next year. I will try and hear results of conference. Any new info here is appreciated
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
After a great premarket open the profit takers have showed up and destroyed the gains from opening. I expect that with those gains they will be back for more. My guess is a nice move up by the end of the day.
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
It's good to know they are still a staff of 17 employees. They will have enough cash on hand to last to 2023. I am sure there will be some momentum with their research by then. This is getting some good news. Looking forward to more.
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
A higher price at closing charts some positive momentum. The after hours continued the trend. Hopefully this stock will begin to grow at higher levels and a new higher resistance base is formed. Fingers and toes crossed. This is the bottom.
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
I am hoping with the conference tomorrow that it will bring some attention to the institutional investors. It has potential to move up this week and I for one have my fingers crossed that they see this as an opportunity to buy more shares. Good luck!!
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
Premarket is up. I hope it will continue throughout the day
šŸ‘ļø0
RockStarInvestor RockStarInvestor 3 years ago
Yeah. I agree. This one attempt has allowed us to get a good price on a up and coming stock. Remember to buy on the news and sell some before the results.
šŸ‘ļø0
EF5$tocks EF5$tocks 3 years ago
Yes--I think we are on the right track for sure with $APRE. Still lots here--way more than the one trial.
šŸ‘ļø0

Your Recent History

Delayed Upgrade Clock